Just a reminder that registrations for the AGPS meeting in Sydney (30 October to 1 November) close this week at midnight (Australian time) on Thursday 16th October. There are still spots available but time is running out!

Now in @Cancer_Cell our group reports the development of a first-in-class EGFR-directed KRAS G12V selective inhibitor. KRAS G12V mutations are the 2nd most common KRAS mutation in cancer, and there are still no approved inhibitors in the clinic. We address two major challenges

https://t.co/co8uD5ObDG Come to Sydney all you GI path junkies - early bird rates end soon!

Tumor deposits are going to be a bigger part of CRC staging going forward- pathologists will need to come to a sharper consensus on their definition/recognition! #GIpath

@IHC_guy HCA vs HCC can be hard on biopsy! But B-catenin mutated should be treated similar to HCC per guidelines #USCAP2025 #liverpath

I’m humbled to have matched to otolaryngology residency @UMichOto! It’s been 27 years since dad and I celebrated his match. Though ALS took you a year ago, we know you’re celebrating with us from above. A million thanks to my family for the support. #Match2025 #IAMOTO #otomatch

https://t.co/kFrXuKaIZM

Calling all Gastrointestinal Pathology enthusiasts. Registration is now open. Don’t miss out. https://t.co/i2QhpqFuD0 #GIPath #PathTwitter #PathX #pathology #pathologist

You know you want to…

Registration is live! https://t.co/ZPmGUTvOLI

Infarct necrosis important to separate from true tumour necrosis in NETs.2 show true necrosis(abrupt transition, karyorrhectic debris, comedo-like)& 2 show infarct(gradual transition, zonal granulation tissue/myobroblasts) If you think easy -> retweet If you think hard -> like

Very pleased to share an excellent online piece brought to you by the CAP Personalized Health Care Committee. By Drs. Matthew Hiemenz and Justin Chang. DNA methylation to the rescue! 🛟 🧬 https://t.co/lbZ495ZU0f #PathTwitter #molpath @Pathologists

NCT06445062: Revolution Medicines trial combining RMC-6236 with either FOLFIRINOX or Gemcitabine/nab-paclitaxel in treatment naive #PancreaticCancer. This study is now open at 17 locations nationwide. Also includes sub-cohorts for #ColorectalCancer and 2nd line pancreatic cancer.

Our journal features two ground-breaking papers in which a molecular link between well-differentiated NETs and high-grade NECs is proposed, arguing that a subset of well-differentiated cases may be at risk of progression! https://t.co/rwLtXUt4mp https://t.co/lYi3YlnXgq

Retroperitoneal tumor adjacent to the VCI in a 40 y/o male. Surgical excision is performed. Tumor is composed of nests and solid areas embedded in a highly vascular stroma, the cytoplasm is granular and partly vacuolated. Rather monotonous nuclei. Follow the thread for more!

So much of ambition is about being exceptional: above average, peerless, “one of a kind” And yet I don’t know if there’s a single word my patients celebrate in their radiology reports more than “unremarkable” Normalcy is underrated

As a patient do you want a physician who works 60-80 hours per week with poor work life balance & emphasis on their career & dedication to craft OR A physician who works 40 hours per week and excellent work life balance who views medicine as a job not their life Tell us why?

Personal opinion badly disguised as evidence forms the bulk of most "evidence-based consensus guidelines" that most doctors blindly accept as truth

Today my memoir, Brainstorm, written with Garry Maddox, is published. I'm thrilled to share my story with you.   Brainstorm tells the story of my life, from my childhood, the road that led me to medicine, my wonderful family, my contributions to medicine and science and my

Looking forward to doing an IM course on my favourite topic in my favourite organ @TheUSCAP in Boston #USCAP2025 - I have a fantastic collection of cases to share on this important entity